Reflexiones nerviosaslo visual : los colores y la cara

Erreferentzia bibliografikoak

• [1] Alcalde J. Colores, salud y comportamiento. 15 de junio de 2004. Accesible en: http://e-ciencia.com/blog/divulgacion/ colores_salud_y_comportamiento_442/
• [2] Cattaneo AD, Lucchelli PE, Filippuci G. Sedative effects of placebo treatment. Eur J ClinPharmacol 1970; 3: 43–45.
• [3] Schapira K, McClelland HA, Griffiths NR, Newell DJ. Study on the effects of tablet colour in the treatment of J. Medrano anxiety states. BMJ 1970; 1(5707): 446–9 [Texto completo en: http://www.ncbi.nlm. nih.gov/pmc/articles/PMC1700499/pdf/brmedj02289-0020.pdf].
• [4] Lucchelli PE, Cattaneo AD, Zattoni J. Effect of capsule colour and order of administration of hypnotic treatments. Eur J ClinPharmacol 1978; 13: 153-5 [Abstract en: http://www.ncbi.nlm.nih.gov/pubmed/26573]
• [5] de Craen AJ, Roos PJ, Leonard de Vries A, Kleijnen J. Effect of colour of drugs: systematic review of perceived effect of drugs and of their effectiveness. BMJ 1996; 313: 1624-6 [Texto completo en: http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC2359128/pdf/bmj00573-0060.pdf].
• [6] Aberasturi A. Un blanco deslumbramiento: palabras para Cris. Madrid: Sial Ediciones, 1999 [Entrevista en http:// www.revistafusion.com/2000/octubre/entrev85.htm]
• [7] Pantalony D. The colour of Medicine. CMAJ 2009; 181: 402-3 [Texto complete en: http://www.cmaj.ca/content/181/6-7/402.full]
• [8] Barrick CB, Taylor D, Correa EI. Color sensitivity and mood disorders: biology or metaphor? J Affect Disord 2002; 68: 67-71 [Abstract en: http://www.ncbi. nlm.nih.gov/pubmed/11869784?dopt=Abstract]
• [9] Keegan DA, Bannister SL. Effect of colour coordination of attire with poster presentation on poster popularity. CMAJ 2003 169: 1291-1292. [Texto complete en: http://www.cmaj.ca/content/169/12/1291.full]
• [10] Furness S, Connor J, Robinson E, Norton R, Ameratunga S, Jackson R. Car colour and risk of car crash injury: population based case control study. BMJ 2003; 327: 1455-6 [Texto complete en: http:// www.bmj.com/content/327/7429/1455.full]
• [11] Ambrosini A, Stanghellini G, Langer AI. El Typusmelancholicus de Tellenbach en la actualidad: una revisión sobre la personalidad premórbida vulnerable a la melancolía. Actas EspPsiquiatr 2011; 39: 302-11 [Texto complete en: http://www.actaspsiquiatria.es/repositorio/13/73/ESP/13- 73-ESP-302-311-412140.pdf]
• [12] Finzi E, Wasserman E. Treatment of depression with botulinum toxin A: a case series. DermatolSurg 2006; 32: 645-9 [Abstract en http://www.ncbi.nlm.nih.gov/ pubmed/16706759]
• [13] Wollmer MA, de Boer C, Ka- lak N, Beck J, Götz T, Schmidt Tet al. Facing depression with botulinum toxin: a randomized controlled trial. J Psychiatr Res. 2012; 46: 574–581 [Texto complete en: http://www.journalofpsychiatricresearch. com/article/S0022-3956(12)00038-6/pdf].
• [14] Magid M, Reichenberg JS, Poth PE, Robertson HT, LaViolette AK, Kruger TH, et al. Treatment of major depressive disorder using botulinum toxin A: a 24- week randomized, double-blind, placebo-controlled study. J Clin Psychiatry [published online ahead of print May 13, 2014] [Abstract en http://www.ncbi.nlm.nih.gov/ pubmed/24910934].
• [15] Wollmer MA, Kalak N, Jung S, de Boer C, Magid M, Reichenberg JS, et al. Agitation predicts response of depression to botulinum toxin treatment in a randomized controlled trial. Front Psychiatry 2014; 5: 36 [Textocomplete en http://www.ncbi. nlm.nih.gov/pmc/articles/PMC3978251/ pdf/fpsyt-05-00036.pdf].
• [16] Greden JF, Genero N, Price HL. Agitation-Increased Electromyogram Activity in the Corrugator Muscle Region: A Possible Explanation of the “Omega Sign”? Am J Psychiatry 1985; 142: 348-51 [Abstract en: http://www.ncbi.nlm.nih.gov/ pubmed/3970275].
• [17] Finzi E, Rosenthal NE. Treatment of depression with onabotulinumtoxin A: a randomized, double-blind, placebo controlled trial. J Psychiatr Res 2014; 52: 1-6 [Abstract en http://www.ncbi.nlm.nih. gov/pubmed/24345483]
• [18] Hennenlotter A, Dresel C, Castrop F, Ceballos-Baumann AO, Wohlschläger AM, Haslinger B. The link between facial feedback and neural activity within central circuitries of emotion--new insights from botulinum toxin-induced denervation of frown muscles. CerebCortex 2009; 19: 537-42 [Texto complete en http:// cercor.oxfordjournals.org/cgi/pmidlookup? view=long&pmid=18562330].
• [19] Shin LM, Liberzon I. The neurocircuitry of fear, stress, and anxiety disorders. Neuropsychopharmacology 2010; 35: 169–191 [Texto complete en: http:// www.nature.com/npp/journal/v35/n1/full/ npp200983a.html].
• [20] Sheline YI, Barch DM, Donnelly JM, Ollinger JM, Snyder AZ, Mintun MA. Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study. Biol Psychiatry 2001; 50: 651–658. [Abstract en: http://www.ncbi. nlm.nih.gov/pubmed/11704071]
• [21] Young SN. Single treatments that have lasting effects: some thoughts on the antidepressant effects of ket- amine and botulinum toxin and the anxiolytic effect of psilocybin. J PsychiatryNeurosci 2013; 38: 78-83 [Texto completo en: http://jpn.ca/wp-content/ uploads/2014/04/38-2-78.pdf].
• [22] Friedrich MJ. Research on Psychiatric Disorders Targets Inflammation. Published online July 23, 2014. doi:10.1001/ jama.2014.8276
• [23] Kirkpatrick B. El concepto de esquizofrenia. RevPsiquiatr Salud Ment (Barc.) 2009;2:105-107 [Texto completo en: http://zl.elsevier.es/es/revista/revistapsiquiatria-salud-mental--286/el-conceptoesquizofrenia-13141287-editorial-2009]